Zymeworks Logo_color.png
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
September 18, 2024 06:00 ET | Zymeworks Inc.
VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Logo_color.png
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
September 03, 2024 16:30 ET | Zymeworks Inc.
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Logo_color.png
Zymeworks Announces Participation in Upcoming Investor Conferences
August 22, 2024 06:30 ET | Zymeworks Inc.
VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Logo_color.png
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
August 01, 2024 16:10 ET | Zymeworks Inc.
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a clinical-stage biotechnology company developing a diverse pipeline of novel,...
Zymeworks Logo_color.png
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 01, 2024 16:05 ET | Zymeworks Inc.
Reported $395.9 million in cash resources as of June 30, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Priority Review of...
Zymeworks Logo_color.png
Zymeworks Announces Participation in Upcoming Investor Conferences
July 30, 2024 06:30 ET | Zymeworks Inc.
VANCOUVER, British Columbia, July 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Logo_color.png
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
July 25, 2024 16:30 ET | Zymeworks Inc.
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Logo_color.png
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
July 22, 2024 06:00 ET | Zymeworks Inc.
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Logo_color.png
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
July 11, 2024 06:30 ET | Zymeworks Inc.
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Logo_color.png
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
June 17, 2024 06:00 ET | Zymeworks Inc.
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...